Coronavirus 2019 (COVID-19) patients are at risk of thrombosis. Literature that compares the effectiveness of enoxaparin to unfractionated heparin (UFH) in COVID-19 patients is scarce.
Objective:
We aimed to evaluate the effectiveness and safety of enoxaparin compared with UFH when used at their standard/intermediate dosing in COVID-19 patients.
Methods:
This was a retrospective study conducted at a large COVID-19 center located in Eastern Province, Saudi Arabia. Confirmed COVID-19 cases (≥18 years old) admitted between January and December 2020 were randomly screened for inclusion. Exclusion criteria were patients receiving therapeutic anticoagulation, on chronic anticoagulation, had active bleeding, a platelet count <25 × 109/L, or an incomplete electronic file. The primary endpoint was the occurrence of any thrombotic event (pulmonary embolism, deep venous thrombosis, stroke, or myocardial infarction) or mortality. Secondary endpoints were major or minor bleeding. We applied inverse propensity score weighting (IPTW) with survival analysis to analyze the primary endpoint. Logistic regression was used for the secondary endpoint.
Results:
A total of 980 patients were included (enoxaparin, n = 470 and UFH, n = 510) with a mean age (±SD) of 47.7 (± 12.3) for the enoxaparin arm and 52 (±13.9) for the UFH arm. There was a statistically significant difference in the primary endpoint with an adjusted hazard ratio (aHR) of 0.46 (95%CI: 0.22 to 0.96, P = 0.039) in favor of the enoxaparin arm. There was no statistically significant difference in major or minor bleeding rates between the two arms.
Conclusion and Relevance:
When compared with UFH, enoxaparin was associated with a significant reduction in thrombotic events or mortality among COVID-19 patients. The results need confirmation from randomized controlled trials.
TsangHFChanLWCChoWCS, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2021;19(7):877-888. doi:10.1080/14787210.2021.1863146.
2.
ChannappanavarRPerlmanS. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-539. doi:10.1007/s00281-017-0629-x.
3.
CuiSChenSLiXLiuSWangF. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424. doi:10.1111/jth.14830.
4.
OpalSM. Interactions between coagulation and inflammation. Scand J Infect Dis. 2003;35(9):545-554. doi:10.1080/00365540310015638.
5.
SpyropoulosACLevyJHAgenoW, et al. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865. doi:10.1111/jth.14929.
6.
MooresLKTritschlerTBrosnahanS, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158(3):1143-1163. doi:10.1016/j.chest.2020.05.559.
7.
MooresLKTritschlerTBrosnahanS, et al. Thromboprophylaxis in patients with COVID-19. Chest. 2022;162(1):213-225. doi:10.1016/j.chest.2022.02.006.
8.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Accessed June 6, 2022. https://www.covid19treatmentguidelines.nih.gov/.
9.
SpyropoulosACGoldinMGiannisD, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612-1620. doi:10.1001/jamainternmed.2021.6203.
10.
RentschCTBeckmanJATomlinsonL, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021;372:n311. doi:10.1136/bmj.n311.
11.
BeinrohrLMurray-RustTADyksterhuisL, et al. Serpins and the complement system. Methods Enzymol. 2011;499:55-75. doi:10.1016/B978-0-12-386471-0.00004-3.
12.
SzajekAYChessEJohansenK, et al. The US regulatory and pharmacopeia response to the global heparin contamination crisis HHS Public Access Author manuscript. Nat Biotechnol. 2016;34(6):625-630. doi:10.1038/nbt.3606.
13.
Braz-de-MeloHAFariaSSPasquarelli-do-NascimentoGSantosIOKobingerGPMagalhãesKG. The use of the anticoagulant heparin and corticosteroid dexamethasone as prominent treatments for COVID-19. Front Med (Lausanne). 2021;8:615333. doi:10.3389/fmed.2021.615333.
14.
MousaviSMoradiMKhorshidahmadTMotamediM. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci. 2015;2015:507151. doi:10.1155/2015/507151.
15.
LopesRDde Barros e SilvaPGMFurtadoRHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253-2263. doi:10.1016/S0140-6736(21)01203-4.
16.
SkrivankovaVWRichmondRCWoolfBAR, et al. Strengthening the reporting of observational studies in epidemiology using Mendelian Randomization: the STROBE-MR statement. JAMA. 2021;326(16):1614-1621. doi:10.1001/JAMA.2021.18236.
17.
HannanEL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv. 2008;1(3):211-217. doi:10.1016/j.jcin.2008.01.008.
18.
VassarMHolzmannM. The retrospective chart review: important methodological considerations. J Educ Eval Health Prof. 2013;10:12. doi:10.3352/jeehp.2013.10.12.
19.
AltmanDGBlandJM. How to randomise. Br Med J. 1999;319(7211):703-704. doi:10.1136/BMJ.319.7211.703.
20.
HarrisPATaylorRMinorBL, et al. The REDCap consortium: building an international community of software platform partners graphical abstarct HHS Public Access. J Biomed Inf. 2019;95:103208. doi:10.1016/j.jbi.2019.103208.
21.
CukerATsengEKNieuwlaatR, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv. 2022. doi:10.1182/BLOODADVANCES.2022007561.
SchulmanSKearonC; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694. doi:10.1111/J.1538-7836.2005.01204.X.
24.
AustinPCStuartEA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661-3679. doi:10.1002/SIM.6607.
25.
van BuurenSGroothuis-OudshoornK. mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1-67. doi :10.18637/jss.v045.i03.
26.
ColeSRHernánMA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656-664. doi:10.1093/AJE/KWN164.
27.
Van Der WeeleTJDingP. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274. doi:10.7326/M16-2607.
PishgarFGreiferNLeyratCSE. MatchThem: Matching and Weighting Multiply Imputed Datasets. R Package Version 1.0.1. Accessed June 6, 2022. https://github.com/FarhadPishgar/MatchThem.
32.
GreiferN. Covariate balance tables and plots: a guide to the cobalt package. 2020;4.3.2. Accessed June 6, 2022. https://ngreifer.github.io/cobalt/.
33.
TritschlerTMathieuMESkeithL, et al. Anticoagulant interventions in hospitalized patients with COVID-19: a scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost. 2020;18(11):2958-2967. doi:10.1111/jth.15094.
34.
ThachilJTangNGandoS, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026. doi:10.1111/JTH.14810.
35.
LaporteSLiotierJBertolettiL, et al. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients. J Thromb Haemost. 2011;9(3):464-472. doi:10.1111/j.1538-7836.2011.04182.x.
36.
ShiCWangCWangH, et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study. Clin Transl Sci. 2020;13(6):1087-1095. doi:10.1111/cts.12880.
37.
HochartHVincent JenkinsPSmithOPWhiteB. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-κB in LPS-stimulated human monocytes. Br J Haematol. 2006;133(1):62-67. doi:10.1111/J.1365-2141.2006.05959.X.
38.
KolliasAKyriakoulisKGDimakakosEPoulakouGStergiouGSSyrigosK. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020;189(5):846-847. doi:10.1111/bjh.16727.
39.
HelmsJTacquardCSeveracF, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098. doi:10.1007/s00134-020-06062-x.
40.
ArmstrongKAMetlayJP. Annals clinical decision making: communicating risk and engaging patients in shared decision making. Ann Intern Med. 2020;172(10):688-692. doi:10.7326/M19-3495.
41.
DesaiRJFranklinJM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657. doi:10.1136/bmj.l5657.
42.
Madley-DowdPHughesRTillingKHeronJ. The proportion of missing data should not be used to guide decisions on multiple imputation. J Clin Epidemiol. 2019;110:63-73. doi:10.1016/j.jclinepi.2019.02.016.
43.
AssiriAAl-TawfiqJAAlkhalifaM, et al. Launching COVID-19 vaccination in Saudi Arabia: lessons learned, and the way forward. Travel Med Infect Dis. 2021;43:102119. doi:10.1016/j.tmaid.2021.102119.
44.
ObeidDAAlsaneaMSAlnemariRT, et al. SARS-CoV-2 genetic diversity and variants of concern in Saudi Arabia. J Infect Dev Ctries. 2021;15(12):1782-1791. doi:10.3855/jidc.15350.
45.
AlyamiMHNaserAYOrabiMAAAlwafiHAlyamiHS. Epidemiology of COVID-19 in the Kingdom of Saudi Arabia: an ecological study. Front Public Health. 2020;8:506. doi:10.3389/fpubh.2020.00506.
46.
FernandesQInchakalodyVPMerhiM, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54(1):524-540. doi:10.1080/07853890.2022.2031274.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
